Which has more human data?

Going by the research status on each profile (BPC-157: Preclinical (animal); TB-500: Preclinical (animal)), they carry the same label, so the status alone does not separate them. Each profile's References section lists the studies, with the species and study type.

What are the half-lives?

BPC-157: Elimination t1/2 < 30 min (rats and beagle dogs, IV and IM); IM bioavailability ~14-19% rats, 45-51% dogs. TB-500: No published PK data found. Figures are as reported in the cited studies, with the species where stated.

Are they FDA-approved?

BPC-157: research status “Preclinical (animal)”. Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026. TB-500: research status “Preclinical (animal)”. Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026. See the FDA peptide regulatory tracker for sourced compounding status.

How are they administered in the research?

BPC-157: Subcutaneous injection. TB-500: Subcutaneous injection. This describes the published studies and is not a recommendation for human use.

How do their proposed mechanisms differ?

BPC-157: In plain terms: Animal and cell studies suggest it may support blood-vessel growth and healing signals; this has not been tested in controlled human trials. Proposed mechanisms, from preclinical (animal and cell) studies, not tested in controlled human trials: angiogenesis, endothelial protection, increased growth-factor expression (including VEGF and EGF), and interaction with the nitric oxide and dopamine systems. A 2026 orthopaedic review notes that clinical trials are lacking (Rahman 2026). TB-500: In plain terms: It is a fragment of thymosin beta-4; studies of the full protein suggest roles in cell movement and healing. Proposed mechanism, from studies of full-length thymosin β4 rather than TB-500 itself: actin binding, promotion of cell migration, and anti-inflammatory activity. In a rat full-thickness wound model, thymosin β4 increased re-epithelialisation (Malinda 1999). These are mechanisms proposed in the cited research, at the research stage listed for each compound.

BPC-157 vs TB-500: Research Comparison

Q: Are they FDA-approved?

BPC-157: research status “Preclinical (animal)”. Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026. TB-500: research status “Preclinical (animal)”. Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026. See the FDA peptide regulatory tracker for sourced compounding status.

Q: How are they administered in the research?

BPC-157: Subcutaneous injection. TB-500: Subcutaneous injection. This describes the published studies and is not a recommendation for human use.

Q: How do their proposed mechanisms differ?

BPC-157: In plain terms: Animal and cell studies suggest it may support blood-vessel growth and healing signals; this has not been tested in controlled human trials. Proposed mechanisms, from preclinical (animal and cell) studies, not tested in controlled human trials: angiogenesis, endothelial protection, increased growth-factor expression (including VEGF and EGF), and interaction with the nitric oxide and dopamine systems. A 2026 orthopaedic review notes that clinical trials are lacking (Rahman 2026). TB-500: In plain terms: It is a fragment of thymosin beta-4; studies of the full protein suggest roles in cell movement and healing. Proposed mechanism, from studies of full-length thymosin β4 rather than TB-500 itself: actin binding, promotion of cell migration, and anti-inflammatory activity. In a rat full-thickness wound model, thymosin β4 increased re-epithelialisation (Malinda 1999). These are mechanisms proposed in the cited research, at the research stage listed for each compound.

Built from the BPC-157, TB-500 research profiles · Profiles last updated October 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team

TL;DR

This page compares BPC-157 and TB-500 using only their research-profile data. BPC-157 (research stage: Preclinical (animal); half-life: Under 30 min (rats and beagle dogs, IV and IM)). Animal and cell studies suggest it may support blood-vessel growth and healing signals; this has not been tested in controlled human trials. TB-500 (research stage: Preclinical (animal); half-life: Not established in published research). It is a fragment of thymosin beta-4; studies of the full protein suggest roles in cell movement and healing. Educational summary, not medical advice.

Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies

Educational summary. Everything below is taken from each compound's research profile and describes what was reported in the cited studies — not a promise of results, a dose recommendation, or an endorsement for human use. Not medical advice. Full disclaimer.

Side-by-side comparison

	BPC-157	TB-500
Category	Healing	Healing
Research status	Preclinical (animal)	Preclinical (animal)
Regulatory note (as of Sept 2026)	Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026. Regulatory tracker →	Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026. Regulatory tracker →
Half-life	Elimination t1/2 < 30 min (rats and beagle dogs, IV and IM); IM bioavailability ~14-19% rats, 45-51% dogs	No published PK data found
Administration route	Subcutaneous injection	Subcutaneous injection
Dosing used in published research (not a recommendation)	Rodent studies dose per kg (commonly µg/kg or ng/kg, i.p. or oral); He et al. 2022 used single and repeated IM doses in rats/dogs. No human dose-finding study in PubMed.	All cited human data are for full-length thymosin β4 given i.v. at 42-1260 mg, single dose or daily for 14 days, n=40 healthy volunteers (Ruff 2010). Tβ4 was given topically or i.p. in rats (Malinda 1999). No published study doses TB-500 (the fragment) in humans.
Community-reported protocol (not from clinical studies)	Community-reported250–500 mcg, subcutaneous injection	Community-reported2–5 mg per week, subcutaneous injection
How it works (as summarized from the cited research)	In plain terms: Animal and cell studies suggest it may support blood-vessel growth and healing signals; this has not been tested in controlled human trials. Proposed mechanisms, from preclinical (animal and cell) studies, not tested in controlled human trials: angiogenesis, endothelial protection, increased growth-factor expression (including VEGF and EGF), and interaction with the nitric oxide and dopamine systems. A 2026 orthopaedic review notes that clinical trials are lacking (Rahman 2026).	In plain terms: It is a fragment of thymosin beta-4; studies of the full protein suggest roles in cell movement and healing. Proposed mechanism, from studies of full-length thymosin β4 rather than TB-500 itself: actin binding, promotion of cell migration, and anti-inflammatory activity. In a rat full-thickness wound model, thymosin β4 increased re-epithelialisation (Malinda 1999).
Effects reported in research (study subjects as stated)	Lab / animalIn rodent injury models, BPC-157 was associated with faster healing; not demonstrated in human trials. Lab / animalIn animal studies: gut health support Lab / animalIn animal studies: reduced inflammation	Lab / animalTissue repair in animal studies of full-length thymosin β4 (not TB-500) Anti-inflammatory signaling reported in studies of full-length thymosin β4 (not TB-500) Lab / animalImproved early cardiomyocyte survival after coronary artery ligation in mice given full-length thymosin β4 (not TB-500)
Potential side effects	Human safety data are limited (no published controlled human safety trials) Lab / animalPreclinical safety evaluated in rats/dogs	Human safety data exist only for full-length Tβ4 (i.v. to 1260 mg: infrequent mild/moderate AEs, Ruff 2010), not TB-500
Profile description	Body Protection Compound-157, a pentadecapeptide derived from human gastric juice that has been studied in animal models of tissue injury.	Synthetic fragment of thymosin beta-4 (Tβ4). Studies of full-length thymosin β4 (not the TB-500 fragment) reported effects on tissue repair, cell migration and inflammation; TB-500 itself has no published human trials.
References cited on the profile	2	3

Key differences in the published research

Research status: the same on every profile (Preclinical (animal)).
Category: the same on every profile (Healing).
Reported half-life: BPC-157 — Elimination t1/2 < 30 min (rats and beagle dogs, IV and IM); IM bioavailability ~14-19% rats, 45-51% dogs; TB-500 — No published PK data found.
Administration route in the literature: the same on every profile (Subcutaneous injection).
Evidence cited: BPC-157’s profile lists 2 references; TB-500’s profile lists 3 references.

Regulatory status

BPC-157: On the FDA peptide regulatory tracker: Removed from Category 2; PCAC recommended for the 503A Bulks List; awaiting FDA rulemaking. Details →
TB-500: On the FDA peptide regulatory tracker: Removed from Category 2; PCAC recommended for the 503A Bulks List; awaiting FDA rulemaking. Details →

For the sourced, dated status of every peptide in FDA's 2026 compounding actions, see the FDA peptide regulatory tracker.

Frequently Asked Questions

Which has more human data?: Going by the research status on each profile (BPC-157: Preclinical (animal); TB-500: Preclinical (animal)), they carry the same label, so the status alone does not separate them. Each profile's References section lists the studies, with the species and study type.
What are the half-lives?: BPC-157: Elimination t1/2 < 30 min (rats and beagle dogs, IV and IM); IM bioavailability ~14-19% rats, 45-51% dogs. TB-500: No published PK data found. Figures are as reported in the cited studies, with the species where stated.
Are they FDA-approved?: BPC-157: research status “Preclinical (animal)”. Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026. TB-500: research status “Preclinical (animal)”. Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026. See the FDA peptide regulatory tracker for sourced compounding status.
How are they administered in the research?: BPC-157: Subcutaneous injection. TB-500: Subcutaneous injection. This describes the published studies and is not a recommendation for human use.
How do their proposed mechanisms differ?: BPC-157: In plain terms: Animal and cell studies suggest it may support blood-vessel growth and healing signals; this has not been tested in controlled human trials. Proposed mechanisms, from preclinical (animal and cell) studies, not tested in controlled human trials: angiogenesis, endothelial protection, increased growth-factor expression (including VEGF and EGF), and interaction with the nitric oxide and dopamine systems. A 2026 orthopaedic review notes that clinical trials are lacking (Rahman 2026). TB-500: In plain terms: It is a fragment of thymosin beta-4; studies of the full protein suggest roles in cell movement and healing. Proposed mechanism, from studies of full-length thymosin β4 rather than TB-500 itself: actin binding, promotion of cell migration, and anti-inflammatory activity. In a rat full-thickness wound model, thymosin β4 increased re-epithelialisation (Malinda 1999). These are mechanisms proposed in the cited research, at the research stage listed for each compound.

References

BPC-157

Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs
He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K et al. Frontiers in pharmacology. 2022. PMID: 36588717.
Study type: PK study, rats and beagle dogs (IV and IM).
DOI: 10.3389/fphar.2022.1026182 · PubMed
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200.
Study type: Narrative review.
DOI: 10.5435/JAAOSGlobal-D-25-00236 · PubMed

TB-500

A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers
Ruff D, Crockford D, Girardi G, Zhang Y. Annals of the New York Academy of Sciences. 2010. PMID: 20536472.
Study type: Phase 1 RCT, n=40, i.v. full-length Tβ4.
DOI: 10.1111/j.1749-6632.2010.05474.x · PubMed
Thymosin beta4 accelerates wound healing
Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL et al. The Journal of investigative dermatology. 1999. PMID: 10469335.
Study type: Rat full-thickness wound model.
DOI: 10.1046/j.1523-1747.1999.00708.x · PubMed
Thymosin beta 4 and the eye: the journey from bench to bedside
Sosne G. Expert opinion on biological therapy. 2018. PMID: 30063853.
Study type: Review.
DOI: 10.1080/14712598.2018.1486818 · PubMed

Read the full profiles

From Our Affiliated Clinic

Prefer physician oversight for peptide therapy?

1836 Wellness — operated by the same company as The Peptide Dispatch — offers physician-supervised protocols, 76-marker blood panels, and bio-age scoring.

Visit 1836 Wellness →

Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.

Educational content — not medical advice. Effects described are drawn from cited research in study subjects.

← Compare Peptides Peptide Database Regulatory Tracker Home